Trials / Completed
CompletedNCT01818986
Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- University of Texas Southwestern Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
In this i-SABR (immunotherapy + Stereotactic Ablative Body Radiation) trial, the stereotactic radiation to multiple metastatic sites is delivered not only to eradicate sites of bulky progressive disease, but also to provide antigen presentation and immune stimulation which is expected to act synergistically to the concurrently administered immunotherapy Sipuleucel-T and thereby significantly improve the treatment outcome for metastatic castrate resistant prostate cancer patients (mCRPC). Both Sipuleucel-T and SABR are FDA approved therapeutic cancer treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sipuleucel-T | |
| RADIATION | Stereotactic Ablative Body Radiation |
Timeline
- Start date
- 2013-07-10
- Primary completion
- 2019-12-20
- Completion
- 2021-05-25
- First posted
- 2013-03-27
- Last updated
- 2022-05-06
- Results posted
- 2022-05-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01818986. Inclusion in this directory is not an endorsement.